| Autor: |
José Viña, Joaquín Escudero, Miquel Baquero, JA Carbonell-Asíns, Francisco J. Tarazona-Santabalbina, Mónica Cebrián, José Enrique Muñoz, Encarnación Satorres, Juan Carlos Melendez, José Ferrer Rebolleda, Ma. del Puig Cózar Santiago, Jose Manuel Santabárbara Gomez, Mariona Jové, Reinald Pamplona, Consuelo Borrás |
| Rok vydání: |
2022 |
| DOI: |
10.1101/2022.06.01.22275832 |
| Popis: |
BackgroundDelaying the transition from minimal cognitive impairment to Alzheimer’s dementia is a major concern in Alzheimer’s disease (AD) therapeutics.Pathological signs of AD occur years before the onset of clinical dementia. Thus, long-term therapeutic approaches, with safe, minimally invasive, and yet effective substances are recommended. There is a need to develop new drugs to delay Alzheimer’s dementia. We have taken a nutritional supplement approach with genistein, a chemically defined polyphenol that acts by multimodal specific mechanisms. Our group previously showed that genistein supplementation is effective to treat the double transgenic (APP/PS1) AD animal model.MethodsIn this double-blind, placebo-controlled, bicentric clinical trial we evaluated the effect of daily oral supplementation with 120 mg of genistein for 12 months on 24 early symptomatic Alzheimer’s patients. We used a battery of validated neurocognitive tests: Mini-Mental State Exam (MMSE), Memory Alteration Test (M@T) Clock-drawing test, Complutense Verbal Learning Test (TAVEC), Barcelona Test-Revised (TBR), and Rey Complex Figure Test.ResultsWe report that genistein treatment results in a significant improvement in two of the tests used (dichotomized direct TAVEC, p=0.031; dichotomized delayed centil REY copy p=0.002 and a tendency to improve in all the rest of them.The amyloid-beta deposition was analyzed using 18F-flutemetamol uptake which showed that genistein-treated patients did not increase their uptake in the anterior cingulate gyrus after treatment (p = 0.878) while placebo-treated did increase it (p=0.036) We did not observe significant changes in other brain areas studiedConclusionsThis study shows that genistein may have a role in therapeutics to delay the onset of Alzheimer’s dementia in patients with mild cognitive impairment. These encouraging results indicate that this should be followed up by a new study with more patients to further validate the conclusion that arises from this study.Trial registrationNCT01982578 |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
